FDA steps up assessment of myocarditis following mRNA COVID-19 jabs

Publication date: Jul 04, 2025

The US Food and Drug Administration (FDA) has provided an update on the risk of myocarditis after receiving an mRNA COVID-19 vaccine, noting the risk is higher in young men. Indeed, the agency is to carry out a benefit-risk assessment on these jabs based on the latest reported rates of myocarditis and pericarditis from the 2023-2024 season, which number around 8. 4 per million vaccine doses. Declin .. .

Concepts Keywords
Fda Administration
Food Assessment
Myocarditis Covid
Vaccination Drug
Fda
Food
Jabs
Mrna
Myocarditis
Provided
Rates
Receiving
Risk
Update
Vaccine

Semantics

Type Source Name
drug DRUGBANK Pirenzepine
disease MESH PANIC
disease IDO object
disease IDO site
disease MESH COVID-19
disease MESH myocarditis

(Visited 3 times, 1 visits today)